Medibulletin brings to you the complete list of 42 anti-cancer drugs under price control as per recent NPPA order
The complete list of 42 anti-cancer drugs under price control covers most common cancers. Last month, the National Pharmaceutical Pricing Authority, invoked extraordinary powers in public interest and brought 42 non-scheduled cancer drugs under price control.
It invoked the powers in “public interest” as per provisions of the Para 19 of the
Drugs (Prices Control) Order, 2013 to bring 42 non-scheduled anti-cancer drugs under
price control, through Trade Margin Rationalisation.
So far, 57 anti-cancer drugs are already under price control as scheduled
formulations. 42 non-scheduled anti-cancer medicines have now been selected for
price regulation by restricting trade margin on the selling price (MRP) up to 30%.
These would cover 72 formulations and 355 brands as per data available with NPPA.
More data is being collected from hospitals and manufacturers to finalise the list.
The scheduled formulations currently under price cap form 16 to 17 per cent of the pharma industry. There has been a long standing demand from consumers and the courts for bringing the remaining segment of non-scheduled drugs under price regulation
The manufacturers have been given seven days to recalculate the prices and
inform the NPPA, State Drug Controllers, stockists and retailers. The revised prices
shall come into effect from 8 th March, 2019.
As per data available with NPPA, the MRP for 105 brands will be reduced up to
85%. This would provide a saving of minimum Rs.105 crore to consumers.
Percentage wise reduction in prices of brands is as follows:
| S.No. | Slab-percentage reduction in prices | No. of Brands |
| 1 | 70% and above | 5 |
| 2 | 50% to 70% | 12 |
| 3 | 25% to 50% | 43 |
| 4 | Up to 25% | 45 |
| TOTAL | 105 |
The NPPA currently fixes prices of drugs placed in the National List of Essential
Medicines under Schedule-I of the DPCO. So far, around 1000 drugs have been price
capped through this modality. The NPPA ensures that the annual price increase in
respect of scheduled formulations is not more than Wholesale Price Index. Additionally,
NPPA also monitors and ensures that price increase in respect of the non-scheduled drugs is not more than 10% per annum.
The scheduled formulations currently under price cap form 16 to 17 per cent of the pharma industry. There has been a long standing demand from consumers and the courts for bringing the remaining segment of non-scheduled drugs under price regulation to save the consumers from arbitrary pricing by the drug manufacturers.
The current intervention is being undertaken as Pilot for ‘Proof of Concept’ for
Trade Margin Rationalisation.
The complete list of 42 anti-cancer drugs under price control
1. Azacitidine
2. Bendamustine Hydrochloride
3. Bortezomib
4. Crizotinib
5. Cytarabine
6. Dasatinib
7. Decitabine
8. Doxorubicin HCI Pegylated Liposomal Injection
9. Enzalutamide
10. Epirubicin
11. Eribulin mesylate
12. Erlotinib HCI
13. Estramustine phosphate
14. Everolimus
15. Exemestane
16. Fulvestrant
17. Irinotecan HCI Trihydrate
18. Lapatanib
19. Leuprolide acetate depot for Inj.
20. Lomustine
21. Mitoxantrone
22. Nilotinib
23. Plerixafor
24. Carfilzomib
25. Cladribine
26. Triptorelin
27. Pomalidomide
28. Osimertinib
29. Pegasperagase
30. Regorafenib
31. Ribociclib
32. Clofarabine
33. Sunitinib
34. Olaparib
35. Olaratumab
36. Paclitaxel (Protein-bound particles)
37. Cabazitaxel
38. Bevacizumab
39. Lenalidomide
40. Pegfilgrastim
41. Mitomycin
42. Pemetrexed
